114 results
6-K
EX-10.2
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
by the other party for their reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution
6-K
EX-10.1
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding, such as a deposition), whether … on Schedule 3.1(j), there is no action, suit, inquiry, notice of violation, proceeding or, to the knowledge of the Company, investigation pending
6-K
EX-5.2
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
, fully paid and non-assessable. Except as expressly set forth herein, we have not undertaken any independent investigation to determine the existence
20-F/A
2023 FY
EX-2.1
BLRX
Bioline Rx Ltd
26 Mar 24
Annual report (foreign) (amended)
4:57pm
, incurred by him as a result of an investigation or proceeding instituted against him by an authority empowered to conduct an investigation or proceedings
20-F/A
2023 FY
BLRX
Bioline Rx Ltd
26 Mar 24
Annual report (foreign) (amended)
4:57pm
Center, or MD Anderson, we entered into an additional collaboration for the investigation of motixafortide in combination with KEYTRUDA in pancreatic … investigation plan agreed to by the relevant European authorities. This does not apply if the product is subject to an agreed waiver or deferral
F-3
b3fx5bgtafu4u4hh
29 Dec 23
Shelf registration (foreign)
4:15pm
6-K
EX-99
dfrzksp
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
qqizywgg
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
59iyv
30 Aug 23
Current report (foreign)
6:45am
6-K
EX-99
gyh oqrwpb5mj3
30 Aug 23
Current report (foreign)
6:45am
6-K
EX-99
laarwr2nlki i641ui
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
g0x28st
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
6-K
EX-10.1
8y2d96x
21 Sep 22
Current report (foreign)
8:00am
6-K
EX-5.2
phirrgao0jkhf2 9d23
21 Sep 22
Current report (foreign)
8:00am
424B5
hxr2a9mm024cz2hgepjb
20 Sep 22
Prospectus supplement for primary offering
4:30pm
6-K
EX-99
awoxmqrzdtn37q
16 Aug 22
BioLineRx Reports Second Quarter 2022 Financial Results
7:19am
6-K
EX-99
r776fv 65bifr37w
11 May 22
BioLineRx Reports First Quarter 2022 Financial Results
7:14am